Clinical Trial Update: TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of TPIV200/huFR-1 vaccine plus durvalumab in platinum-resistant ovarian cancer completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• TPIV200/huFR-1

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-11-30